

## Anti-Mutagenic Activity of *Phyllanthus amarus* Schum & Thonn In Vitro as Well as In Vivo

K. Regi Raphael, T.A. Ajith, Swarnam Joseph, and Ramadasan Kuttan\*  
Amala Cancer Research Centre, Thrissur, Kerala, India

Methanolic extract of *Phyllanthus amarus* was tested for its anti-mutagenic activity in *Salmonella typhimurium* strains TA1535, TA100, and TA 102 (Ames test). *P. amarus* extract was able to inhibit the activation of 2-acetaminofluorene (2-AAF) and aflatoxin B<sub>1</sub> at concentrations of 0.1 mg/ml in the plate. It was also found to inhibit mutagenicity induced by direct acting mutagens sodium azide (NaN<sub>3</sub>), N-methyl-N-nitro-N-nitrosoguanidine (MNNG), 4-nitro-O-phenylenediamine (NPB), at concentrations of 100 µg to 0.25 mg/ml. Urinary mutagenicity produced in rats by benzo[a]pyrene was inhibited by the oral administration of *Phyllanthus* extract. These results indicate significant anti-mutagenicity of the extract in vitro as well as in vivo. *Teratogenesis, Carcinogenesis, and Mutagenesis* 22:285-291, 2002. Wiley-Liss, Inc.

**Keywords:** *Phyllanthus amarus*; mutagenesis; anti-mutagenesis; anti-carcinogen; urinary polyaromatic hydrocarbon; aflatoxin B<sub>1</sub>

### INTRODUCTION

*Phyllanthus amarus* (syn. *Phyllanthus niruri*, Euphorbiaceae) is an important plant in the treatment of liver disorders and jaundice in traditional Indian medicine. It has been effective against infective hepatitis [1]. It is also used in many stomach disorders and diseases of the genitourinary system. The extract was found to have hypoglycemic, antifungal and anticancer activity [2]. The protective effect of *Phyllanthus* has been demonstrated in chemical liver toxicity models [3]. Simultaneous administration of *P. amarus* extract has been reported to inhibit the hepatocellular carcinoma development induced by N-nitrosodiethylamine [4]. *P. amarus* administration was also found to increase the life span of rats with hepatocellular carcinoma [5]. We showed recently that

\*Correspondence to: Dr. Ramadasan Kuttan, Research Director, Amala Cancer Research Centre, Thrissur, Kerala 680 513, India

Received 15 May 2001; Accepted 15 May 2001  
online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/tem.10021



killed on the 5th day, livers were removed aseptically, and microsomal fractions from S9 were prepared [9]. The protein content of the S9 fraction was  $40 \pm 2$  mg/ml as determined by the method of Lowry et al. [11]. 2-AAF (50 µg/plate) and aflatoxin-B<sub>1</sub> (5 µg) were pre-incubated with sodium phosphate buffer (0.2 M, pH 7.4, 200 µl), NADP (0.1 M 25 µl), MgCl<sub>2</sub>-KCl (1.65 M KCl + 0.4 M MgCl<sub>2</sub>, 10 µl), glucose-6-phosphate (1 M, 25 µl), S9 (200 µl), and the bacteria TA1535 (100 µl approximately 10<sup>8</sup> cells) for 10 min at 37°C in the presence of various concentrations of *P. amarus* extract.

The mixture was plated on previously prepared minimal agar plates and incubated at 37°C for 48 h, after which the number of revertants was counted. The percentage inhibition of mutagenicity was calculated using the formula  $\frac{R_1 - R_2}{R_1 - SR} \times 100$ , where R<sub>1</sub> is the number of revertants in the presence of mutagen alone, R<sub>2</sub> is the number of revertants in the presence of mutagen and drug, and SR is the spontaneous revertants.

*P. amarus* extract was also tested for its inhibitory activity or direct acting mutagens MNNG (1 µg/plate), NPDA (20 µg/plate), and sodium azide (2.5 µg/plate) induced revertant formation using *Salmonella* tester strains TA1535, TA100, and TA102 (approximately 10<sup>8</sup> cells) by the method of Maron and Ames [9].

### Determination of Urinary Mutagenicity in Rats

Male Wistar rats were divided into three groups (six rats/group). The group I animals were given distilled water through oral intubation, which served as control. Group II animals were given benzo[a]pyrene (10 mg/rat) by i.p. injection as a single dose. Group III were given *P. amarus* extract (500 mg/kg bwt) for 12 days. On the 13th day benzo[a]pyrene (10 mg/rat) in sun flower oil was administered by i.p. injection as single dose. All the rats were put into metabolic cages and urine samples were collected for 24 h after injection. The samples were frozen immediately and kept at -70°C until analysis.

The urine samples were filtered through Whatman number 1 filter paper and was passed through an XAD-2-Amberlite column to concentrate the mutagens [12].

Twenty milliliters of urine that was collected from a rat was loaded onto an XAD column (40 m<sup>2</sup> x 10 m). The adsorbed components were eluted with 10 ml acetone. The eluants were evaporated to dryness at 60°C and stored at -70°C. They were reconstituted in 1.5 ml dimethyl sulphoxide just before they were used for the mutagenicity assay. To check the mutagenicity 0.1 ml bacteria and 0.1 ml column eluate were mixed with 2 ml top agar containing traces of histidine and biotin plated on minimal agar medium. The revertants were counted after incubation in the dark at 37°C for 48 h.

## RESULTS

### Anti-mutagenicity of *P. amarus* Extract Using Direct Acting Mutagens

**Sodium azide (NaN<sub>3</sub>).** *Phyllanthus* extract was found to reduce the number of revertants produced by sodium azide (2.5 µg/plate) on *S. typhimurium* strains TA 1535, TA100, and TA102. Antimutagenicity was found to be concentration dependent and 50% inhibition was produced at a concentration of 1-2 mg/plate (Table 1).

**TABLE 1.** Anti-Mutagenicity of *Phyllanthus amarus* Extract to *Salmonella typhimurim* Strains Against Sodium Azide as Mutagen

Concentration of the extract(mg/plate)	Average number. of revertants/plate Sodium Azide(2.5µg/plate)		
	TA1535	TA100	TA102
Nil	1039.3±85.6	535.5±40.3	667.5±32.9
0.5	571.7±49.2*	349.0±15.1*	524.0±19.3"
0.25	693.3±34.6**	403.0±11.4	614.0±20.5
Spontaneous revertants	824.7±67.6	494.5±24.7	614.0±20.5
	25.33±3.1	150.5±15.	273.5±18.9

\* $P < 0.001$ .

P &lt; 0.005.

**TABLE II.** Anti-Mutagenicity of *Phyllanthus amarus* Extract to *Salmonella typhimurim* Strains Against N-methyl-N-Nitro-Nitrosoguanidine as Mutagen

Concentration of the extract(mg/plate)	Average number of revertants per plate MNNG (1 µg plate)		
	TA1535	TA 100	TA102
Nil	495.0±21.2	487.5±17.7	566.0±28.3
1	297.0±16.9*	367.5±26.1**	412.0±22.9**
0.5	358.0±18.4*	409.0±12.7*	497.5±18.5
0.25	416.5±12.0**	442.0±19.1	538.3±14.8
Spontaneous revertants	22.6±3.0	173.5±24.5	292.5±26.0

• $P < 0.001$ .

P &lt; 0.005.

N-methyl-N-nitro-N-nitrosoguanidine (MNNG). *P. amarus* extract was also found to inhibit mutagenicity produced by MNNG (1 µg/plate) in a dose dependent manner in different *Salmonella* strains described earlier. Concentration needed for 50% inhibition was found to be 1–2 mg/plate, which was similar to that of sodium azide (Table

4-nitro-0-phenylenediamine (4-NPD). *P. amarus* extract was found to significantly inhibit the mutagenicity induced by NPD (20 µg/plate) to *Salmonella* strains. Concentration needed for 50% inhibition was similar in the other cases which was between 1 and 2 mg/plate (Table 111).

#### Anti-Mutagenicity of *P. amarus* Extract Using Mutagens Which Needed Activation

Mutagenicity produced by 2-AAF and AFB<sub>1</sub> after their activation using S9 fractions was found to be significantly inhibited by *P. amarus* extract. The concentration needed for 50% inhibition of mutagenicity to *Su/mond/a* strain 1535 was found to be only 2 mg/plate in the case of 2-AAF and between 2 and 3 mg/plate in the case of AFB<sub>1</sub> (Table IV).

**TABLE III. Anti-Mutagenicity of *Phyllanthus amarus* Extract to *Salmonella typhimurium* Strains Against 4-Nitro-o-PhenyleneDiamine as Mutagen**

Concentration of the extract(mg/plate)	Average number of revertants per plate NPD (20 µg/plate)		
	TA1535	TA100	TA 102
Nil	392.5 ± 10.6	528.6 ± 17.6	635.0 ± 28.9
	196.0 ± 15.7*	304.0 ± 15.0*	416.5 ± 24.7*
0.5	253.0 ± 23.3*	358.6 ± 22.5	53.10 ± 19.8*
0.25	292.0 ± 12.8	477.6 ± 14.2	590.0 ± 13.2
Spontaneous revertants	26.3 ± 7.2	167.6 ± 17.2	305.5 ± 13.1

\*P&lt;0.001.

**TABLE IV. Anti Mutagenicity of Extracts of *P. amarus* to *Salmonella typhimurium* TA1535 against 2-Acetamidofluorene(2-AAF) and Aflatoxin B<sub>1</sub> as Mutagens**

Concentration of extract(mg plate)	Average number of revertants per plate	
	2-AAF (50 µg/plate)	Aflatoxin (5 µg plate)
Nil	376.0 ± 12.7	261.1 ± 13.5
	190.0 ± 14.5*	168.0 ± 12.5*
1	219.5 ± 17.8*	181.6 ± 20.4
0	254.0 ± 8.5**	205.3 ± 118.5
	308.5 ± 16.3	223.0 ± 17.0
Spontaneous revertants	33.6 ± 7.7	37.0 ± 11.1

\* AAF and AFB<sub>1</sub> were activated with S3 fraction containing NADP and Mg<sup>++</sup>.

\*\*P&lt;0.001.

•P=0.005.

These results indicated that *P. amarus* extract could inhibit the mutagenicity induced by direct acting mutagens and mutagens that needed activation in several *S. typhimurium* strains at low concentrations.

#### Effect of *P. amarus* Extract on Urinary Mutagenicity Induced by Benzo[a]pyrene in Rats

*P. amarus* extract was found to inhibit the urinary mutagenicity induced by benzo[a]pyrene in rats. In this experiment, urine collected from animals treated with benzo[a]pyrene in presence and absence of *P. amarus* extract was tested for mutagenicity three different *Salmonella* strains. Urine from benzo[a]pyrene-treated rats was found to exhibit high mutagenic potential as seen from the increase in number of revertants. Administration of *P. amarus* extract was found to inhibit urinary mutagenicity significantly, which was 46% in the case of TA1535, 73% in the case of TA100, and 100% in the case of TA102 (Table V).

TABLE V. The Effect of Extract of *Phyllanthus amarus* on Urinary Mutagenicity Induced by Benzo[*a*]pyrene in Rate

Group NO	Treatment	Average number of revertants per plate		
		TA1535	TA100	TA102
I	•Normal untreated	56.0±11.3	164.4±14.5	187.5±9.2
II	Control B[ <i>a</i> ]P	336.7±45.1	298.3±12.6	392.3±29.3
III	Drug	193.7±7.1***	198.3±10.4*	247.7±24.4**
	500 mg + B[ <i>a</i> ]P			
	Spontaneous revertants	23.9±2.8	162.6±20.5	283.5±21.7

\*Values are without reducing spontaneous revertants.

\*<sup>1</sup> P<0.001.

— P<0.005.

## DISCUSSION

In the present study, we have evaluated the antimutagenicity of *P. amarus* extract that is being used in hepatic diseases including acute viral hepatitis [13]. Studies on the anti-mutagenic activity of the extract indicated that the extract inhibited the mutagenicity produced by direct acting mutagens such as NaN<sub>3</sub>, MNNG, and 4-NI D and also inhibited the activation of the mutagens such as 2-AAF and AFB<sub>1</sub> by rat liver S9 fraction and thereby inhibited the mutagenesis and possibly carcinogenic potential. Inhibition of mutagenicity of 2-AAF and AFB<sub>1</sub> may be mainly due to inhibition of their activation mediated by P-450 enzymes. Activated metabolites form adducts with DNA and produces mutagenesis and carcinogenesis. In fact we have seen that *P. amarus* extract could inhibit the activation of P-450 enzyme in vitro. *P. amarus* extract also decreased the levels of benzo[*a*]pyrene-induced mutagenesis in urine. This may be due to the inhibition of Phase I enzymes by the extract.

*P. amarus* is extensively used in viral hepatitis. Unander et al. have shown that extract could inhibit the viral polymerase [14] and down-regulate hepatitis p virus mRNA transcription and replication [15]. The *P. amarus* extract has been shown to reverse the chromosomal alteration induced by genotoxic agents [8]. *P. amarus* extract has been reported to possess anti oxidant activities [6] and inhibited aniline hydroxylase a P-450 enzyme responsible for the activation of carcinogens. The extract was reported to inhibit the activity of cdc 25 tyrosine phosphatase, a key enzyme involved in cell cycle regulation [16]. Several active compounds have been identified in *P. amarus* extract. Lignans such as phyllanthin and hypophyllanthin [17], flavanoids such as quercetin and astragaline [18], ellagitannin such as amaric acid [19], and hydrolysable tannins such as phyllanthisiin I [20] and amaritin [21] were reported from *P. amarus*. Some of the hydrolysable tannins have been shown to inhibit signal transduction. The extract was also found to inhibit the activity of topoisomerase I and II in *Saccharomyces cerevisiae* mutant cell cultures [5], indicating that other than the inhibition of the activation of carcinogen the extract has multifocal activity to bring about a reduction in the neoplastic condition in animals and humans.

## REFERENCES

1. Blumberg BS, Milliman 1, Venkateswaran PS, Thyagaragan SP. Hepatitis B virus and primary hepatocellular carcinoma: treatment of HBV carriers with *Phyllanthus amarus*. Vaccine 1990;8:386-392.
2. Bratati De, Datta PC, De B. Pharmacognostic evaluation of *Phyllanthus amarus*. Int J Crud Drug Res 1990;28:81-88.
3. Prakas A, Satyan KS, Wahi SP, Singh RP. Comparative hepatoprotective activity of three *Phyllanthus* species. *P. urinaria*, *P. niruri* and *P. simplex*, on carbon tetrachloride induced liver injury in the rat. Phytotherapy Res 1995;9:594-596.
4. Joy KL, Kuttan R. Inhibition by *Phyllanthus amarus* of hepatocarcinogenesis induced by N-nitrosodiethylamine. J Clin Biochem-Nutr 1998;24:133-139.
5. Rajesh Kumar NV, Kuttan R. *Phyllanthus amarus* extract administration increases the life span of rats with hepatocellular carcinoma. J Ethnopharmacol 2000;73:215-219.
6. Joy KL, Kuttan R. Antioxidant activity of selected plant extracts. Amala Res Bull 1995;15:68-71.
7. Polya GM, Wang BH, Fooley LY. Inhibition of signal regulated protein kinases by plant derived hydrolysable tannins. Phytochemistry 1995;38:307-314.
8. Gowrishanker B, Vivekanandan OS. In vivo studies of a crude extract of *Phyllanthus amarus* L. in modifying the genotoxicity induced in *Vicia faba* L by tannery effluents. Mutat Res 1994;322:185-192.
9. Maron DM, Ames BN. Revised methods for *Salmonella* mutagenicity test. Mutat Res 1983;113:173-215.
10. Ames BN, Purston WE, Yamasaki E, Lee FD. Carcinogens are mutagens: a simple test system combining liver homogenate for activation bacteria for detection. Proc Natl Acad Sciences 1975;72:2281-2285.
11. Lowry DH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
12. Yamasaki E, Ames BN. Concentration of mutagens from urine by absorption with the non polar resin XAD-2: cigarette smokers. Proc Natl Acad Sci USA 1979;74:3555-3559.
13. Jayaram S, Thyagaragan SP, Sumathy S, Manjula S, Malathy S, Madanagopalan N. Efficiency of *Phyllanthus amarus* treatment in acute viral hepatitis A, B and non A and non B: an open clinical trial. Ind J Virol 1997;13:59-64.
14. Unander DW, Venkateswaran PS, Milliman 1, Blumberg BS. Inhibition of hepatitis B virus-dependent DNA polymerase by species of *Phyllanthus*: genetic and environmental effects on this activity. Brenesia 1994;34:21-40.
15. Lee CD, Ott M, Thygarajan SP, Shafritz DA, Burk RD, Gupta S. *Phyllanthus amarus* down regulates hepatitis B virus mRNA transcription and replication. Eur J Clin Invest 1996;26:1069-1076.
16. Jeena Jose K, Joy KL, Ramadasan K. Effect of *Embelia officinalis*, *Phyllanthus canaries*, *Pterorrhiza kurroa* on N-nitroso diethylamine induced hepatocarcinogenesis. Cancer Lett 1999;136:11-16.
17. Somanabandhu A, Nitayangkuru S, Mahidol C, et al. <sup>1</sup>H and <sup>13</sup>C-NMR assignments of phyllanthin and hypophyllanthin: lignans that enhance cytotoxic responses with cultured multidrug-resistant cells. J Nat Products 1993;56:233-236.
18. Nara TK, Glye J, Cervel EL, Sanislao E. Flavanoids of *Phyllanthus niruri*, *Phyllanthus urinaria*, *Phyllanthus orbiculatus*. Plant Med Phytother 1977;11:82-86.
19. Foo LY. Amarinic acid and related ellagitannins from *Phyllanthus amarus*. Phytochemistry 1995;39:217-224.
20. Foo LY, Wong H. Phyllanthin, D, an unusual hydrolysable tannins from *Phyllanthus amarus*. Phytochemistry 1992;31:711-713.
21. Foo LY. Amarin, a di-dehydro hexahydroxy diphenoyl hydrolysable tannin from *Phyllanthus amarus*. Phytochemistry 1993;33:217-224.